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Class A drug abuse – An ophthalmologist’s problem? 
 
The 2002/3 British Crime Survey 1 reported that 3% of all 16 to 59 year olds 
(equating to around one million people) had used a class A drug in the last year. Use 
of a class A drug in the 16-24 year old age group (8%) has remained similar since 
1996. Use of cocaine and crack cocaine are on the increase. For the first time since 
1996 the use of ecstasy has decreased. Poly drug use is not uncommon. During the 
year 2000/1, 118,500 patients were in treatment with drug misuse agencies and 
general practitioners. 2 Ocular sequelae from illicit drug use are varied, affecting 
visual acuity, visual perception, ocular posture or motility, the globe itself or its 
adnexa. 3   Large studies are not available to allow us to quantify the problem, and 
many of the reports are of single cases or small case series. However, an awareness of 
possible problems which may arise from the use of class A drugs may alert the 
clinician to this as the aetiology of a condition presenting to them. 
 
Cocaine and crack cocaine probably have the highest number of ocular problems 
reported from their use. Its sympathomimetic effect has led to acute angle-closure 
glaucoma 4  and its vasoactive properties to spasms of vessels or haemorrhages. These 
may be retinal or in the brain stem, leading to visual loss, 5 which can be transient, 6 or 
ocular motility problems. 7  It’s use may also lead to cerebral vasculitis. 8  It is the 
intense vasoconstriction combined with anaesthesia from the intranasal use of cocaine 
that leads to mucoperichondrial ischaemia and loss of the nasal septum. This may 
extend to the bony walls of the orbit. Nasolacrimal duct obstruction, orbital cellulitis, 
and optic neuropathy can result. 9  Motility problems may not necessarily be vascular. 
Cocaine is known to unmask or exacerbate myasthenia gravis, possibly due to it 
blocking the sodium channels and slowing presynaptic neuronal transmission. 10
 We may be familiar with the use of cocaine as an anaesthetic agent. Decreased 
corneal sensitivity, the direct toxic effect of the smoke, neurotrophic changes or 
vigorous eye rubbing have all been suggested as leading to corneal problems in crack 
cocaine users which may include corneal ulcers, superficial punctate keratitis and 
corneal epithelial defects. 11 Cocaine powder may be introduced into the eye in error 
by contact lens wearers. 12
 
Previously in Eye 13 I reported the onset of esotropia following heroin withdrawal and 
this has since been reported by others. 14,15 A change in the angle of deviation in the 
eso direction at distance, not due to 6th nerve palsy or divergence palsy, has been 
found to occur following a compressed opiate detoxification regime resulting in a 
distance esotopia in some patients. 16 This may then presumably decompensate to a 
constant deviation. Kowal et al 14 reported that diplopia was more common following 
rapid detoxification and so as these programmes gain popularity more patients may 
present. Diplopia may also result from internuclear ophthalmoplegia following heroin 
use, and it’s resolution on use of naltrexone (an opiate blocker) is suggestive that this 
occurs due to an active mechanism. 17
 
Sight threatening conditions can occur in heroin users. Toxic amblyopia may result 
from using quinine either as a cutting agent 18 to make the heroin taste bitter and thus 
of better quality, or to help the muscle cramps in self detoxification attempts. 19 
Metastatic endophthalmitis from the fungus candida albicans, transmitted from lemon 
juice used to prepare the heroin for injection 20 or aspergillus, an air borne fungus 
have been reported. 21
 
Amongst the hallucinogenics fewer problems have been reported. Whilst sun gazing 
under lysergic acid diethylamide (LSD) may lead to solar retinopathy 22 and magic 
mushrooms to closing in of nearby space, 23 it is perceptual changes which cause the 
main problems. Palinopsia, trailing phenomena (discontinuous stationary images that 
trail behind a moving object), hallucinogenic persisting perception disorder (either in 
the form of flash-backs or longer lasting alterations in perception) may occur years 
after use and even after a single episode of LSD use. 24-26 Visual perception disorder 
(hundreds of dots moving over whole visual field), palinopsia and flashbacks have 
also been reported following use of methylenedioxymethampthetamine (MDMA), 
commonly known as ecstasy. 27-29 Retinal haemorrhage following ecstasy use, 
possibly due to a sudden rise in blood pressure, has been reported in a single case. 30 
However, a case of bilateral sixth nerve palsy was attributed to either mild cerebral 
oedema or interaction of MDMA with the seratonin metabolism in the 6th nerve. 31
  
Thus, it is apparent that a variety of ocular complaints may present to an eye casualty 
unit or clinic that are the result of use of class A drugs. Clinicians need to be aware of 
the ocular problems that may be related to drug use in order that pertinent questions 
may be asked regarding the cause.  
 
Alison Y Firth 
Academic Unit of Ophthalmology and Orthoptics 
University of Sheffield 
UK 
a.firth@sheffield.ac.uk 
 
References 
1. Condon J, Smith N. Prevalence of drug use: key findings from the 2002/2003 
British Crime Survey. Home Office Findings 229. London: Home Office. 2003. 
2. Department of Health. Statistical bulletin. Statistics from the regional drug misuse 
databases on drug misusers in treatment in England, 2000/01. London: Department of 
Health, Statistical Bulletin 2001/33. 2001. 
3. Firth AY. Ocular sequelae from the illicit use of class A drugs. Br Orthopt J 2004; 
61: in press. 
4. Mitchell JD, Schwartz AL. Acute angle-closure glaucoma associated with 
intranasal cocaine abuse. Am J Ophthalmol  1996; 122: 425-426. 
5. Michaelides M, Larkin G. Cocaine-associated central retinal artery occlusion in a 
young man. Eye 2002; 16: 790-792. 
6. Libman RB, Masters SR, de Paola A, Mohr JP. Transient monocular blindness 
associated with cocaine abuse. Neurology 1993; 43: 228-9. 
7. Nemeth G, McHenry JG, Zeiter JH, et al: Oculomotor abnormalities secondary to 
crack cocaine. Ophthalmology 1993; 100(suppl): 632. 
8. Krendel DA, Ditter SM, Frankel MR, Ross WK. Biopsy proven cerebral vasculitis 
associated with cocaine abuse. Neurology 1990; 40: 1092-1094. 
9. Alexandrakis G, Tse DT, Roas RH, Johnson TE. Nasolacrimal duct obstruction and 
orbital cellulitis associated with chronic intranasal cocaine abuse. Arch Ophthalmol 
1999; 117: 1617-1622. 
10. Valmaggia C, Gottlob I. Cocaine abuse, generalized myasthenia, complete 
external ophthalmoplegia, and pseudotonic pupil. Strabismus 2001; 9: 9-12. 
11. Sachs R, Zagelbaum BM, Hersch PS. Corneal complications associated with the 
use of crack cocaine. Ophthalmology 1993; 100: 187-191. 
12. Parmar DN, Robinson F, Hunter PA. Microbial keratitis following cocaine abuse 
in a soft contact lens wearer. Eye 1999; 13: 264-265. 
13. Firth AY. Heroin withdrawal as a possible cause of acute concomitant esotropia in 
adults. Eye 2001; 15: 189-192. 
14. Kowal L, Mee J, Nadkarni S, Kozminsky M, Kalff S. Acute esotropia in heroin 
withdrawal. In: de Faber J-T (ed) Progress in Strabismology, Proceedings of the 10th 
International Strabismological Association, Sydney, Australia, April 2002. Swets & 
Zeitlinger, Lisse. 2003: 305-306. 
15. Sutter FKP, Landau K: Heroin and Strabismus. Swiss Med Wkly 2003; 133: 293-
294. 
16. Firth AY, Pulling S, Carr MP, Beaini AY. Orthoptic status pre and immediately 
post heroin detoxification. Br J Ophthalmol 2004; 88: in press. 
17. Rizzo M, Corbett J. Bilateral internuclear ophthalmolpegia reversed by naloxone. 
Arch Neurol 1983; 40: 242-243. 
18. Brust JCM, Richter RW. Quinine amblyopia related to heroin addiction. Annals of 
Internal Medicine 1971; 74: 84-86. 
19. Feeney GFX, Lee GA, O’Connor PA. Quinine-induced blindness during 
attempted heroin withdrawal. Med J Australia  1999; 170: 449. 
20. Martinez-Vazquez C, Fernandez-Ulloa J, Borden J. Candida albicans 
endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and 
followed by antifungal therapy. Clin Infect Dis 1998; 27: 1130-1133. 
21. Sugar HS, Mandell GH, Shalev J. Metastatic endohthalmitis associated with 
injection of addictive drugs. Am J Ophthalmol 1971; 71: 1055-1058. 
22. Schatz H, Mendelblatt F. Solar retinopathy from sun-gazing under the influence of 
LSD. Br J Ophthalmol 1973; 57: 270-273. 
23. Fischer R, Hill R, Thatcher K, Sceib J. Psilocybin-induced contraction of nearby 
visual space. Agents and actions 1970; 1: 190-197. 
24. Asher H. ‘Trailing’ phenomenon – a long-lasting LSD side effect. Am J 
Psychiatry 1971; 127: 1233-1234. 
25. Horowitz MJ. Flashbacks: recurrent intrusive images after the use of LSD. Am J 
Psychiatry 1969; 126: 565-9. 
26. Woody GE. Visual disturbances experienced by hallucinogenic drug abusers 
while driving. Am J Psychiat 1970; 127: 683-686. 
27. Passie T, Schneider U, Emrich HM. Persisting continuous visual perception 
disorder in a chronic MDMA (‘ecstasy’) user. Austalian and New Zealand J 
Psychiatry 2002; 36: 266-267. 
28. McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with the 
use of 3,4-methylenedioxymethamphetamine (‘Ecstasy’). Br J Psychiatry 1994; 165: 
391-395. 
29. Creighton FJ, Black DL, Hyde CE. ‘Ecstasy’ psychosis and flashbacks. Br J 
Psychiatry 1991; 159: 713-715. 
30. Jacks AS, Hykin PG. Retinal haemorrhage caused by ‘ecstasy’. Br J  Ophthalmol 
1998; 82: 842-843. 
31. Schroeder B, Brieden S. Bilateral sixth nerve palsy associated with MDMA 
(“ecstasy”) abuse. Am J Ophthalmol 2000; 129: 408-409. 
 
 
 
 
